Phase 2bData readout

Rapamycin/Sirolimus (LAM-001) (mTOR Inhibitor)

Pulmonary Hypertension Associated With Interstitial Lung Disease

QNCXQuince Therapeutics

Expected catalystMarch 31, 2028Company guidance: Mar 31, 2028

Catalyst overview

Event details

Drug or asset: Rapamycin/Sirolimus (LAM-001) (mTOR Inhibitor)
Development stage: Phase 2b
Event type: Data readout
Indication: Pulmonary Hypertension Associated With Interstitial Lung Disease

Research summary

What is being tracked?

This catalyst tracks a Phase 2b data readout for Rapamycin/Sirolimus (LAM-001) (mTOR Inhibitor) in Pulmonary Hypertension Associated With Interstitial Lung Disease. The expected timing is based on the latest available company guidance and may change.

Development notes

05/18/26:- Phase 2a data showed improved 6MWD/PVR. Phase 2b in PH-ILD to start Mid-2026; topline Q1 2028. 08/14/26:- Phase 2b PH-ILD trial initiated and subjects are screening. Topline data is expected in Q1 2028.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

Phase 2bData readout

Rapamycin/Sirolimus (LAM-001) (mTOR Inhibitor)

Pulmonary Hypertension Associated With Interstitial Lung Disease

QNCXQuince Therapeutics

Expected catalystMarch 31, 2028Company guidance: Mar 31, 2028

Catalyst overview

Event details

Drug or asset: Rapamycin/Sirolimus (LAM-001) (mTOR Inhibitor)
Development stage: Phase 2b
Event type: Data readout
Indication: Pulmonary Hypertension Associated With Interstitial Lung Disease

Research summary

What is being tracked?

Development notes

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

Rapamycin/Sirolimus (LAM-001) (mTOR Inhibitor)

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs

Sirolimus/Rapamycin (LAM-001) (mTOR Inhibitor)